Viewing Study NCT05460767


Ignite Creation Date: 2025-12-25 @ 12:33 AM
Ignite Modification Date: 2026-01-04 @ 8:58 AM
Study NCT ID: NCT05460767
Status: RECRUITING
Last Update Posted: 2023-12-29
First Post: 2022-07-05
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module